Sarepta Therapeutics Appoints Louise Rodino-Klapac, Ph.D. to Lead Newly Created Gene Therapy Business UnitGlobeNewswire (press release)Dr. Rodino-Klapac, a National Institutes of Health Fellow, is a pioneer in the advancement of gene therapy to treat h… Continue reading
CNBC |
Celgene CEO: We don’t have to be No. 1 to thrive with new cancer therapy to replace chemo
CNBC [are] realizing is that this class of medicine of CAR T therapy — whether its lymphoma, leukaemia or myeloma — will replace existing chemotherapy,” Alles said in a “Squawk Box” interview. CAR T-cell therapy takes a patient’s own immune cells, called … |
Genetic Literacy Project |
As world’s scientists herald CRISPR revolution, will Africa follow?
Genetic Literacy Project I am only wondering if those spreading the misinformation are currently following the recent “super” GMO technique referred to as Clusters of Regularly Interspaced Short Palindromic Repeats (CRISPR), which is being hailed and accepted worldwide. And … |
Seeking Alpha |
3 Things In Biotech, June 3: CAR–T Cell Therapy Revs Up Again
Seeking Alpha News: Legend Biotech announced that the FDA has allowed JNJ’s Janssen to commence with a phase 1b/2 study involving its developmental CAR–T cell therapy called LCAR-B38M. This trial will enroll patients with relapsed or refractory multiple myeloma. |
|
Neuralstem’s NSI-566 stem cell therapy confers neurological improvement in spinal cord injury patients with complete …
GlobeNewswire (press release) Neuralstem Announces Publication of Data From First-In-Human Study of Human Neural Stem Cell Transplantation for Chronic Spinal Cord Injury -. – First cohort of four subjects with thoracic (T2-T12) ASIA-A grade spinal cord injury in the Phase I study … |